Wells Fargo & Company Amylyx Pharmaceuticals, Inc. Transaction History
Wells Fargo & Company
- $407 Billion
- Q2 2024
A detailed history of Wells Fargo & Company transactions in Amylyx Pharmaceuticals, Inc. stock. As of the latest transaction made, Wells Fargo & Company holds 300 shares of AMLX stock, worth $882. This represents 0.0% of its overall portfolio holdings.
Number of Shares
300
Previous 20,949
98.57%
Holding current value
$882
Previous $59,000
100.0%
% of portfolio
0.0%
Previous 0.0%
Shares
10 transactions
Others Institutions Holding AMLX
# of Institutions
140Shares Held
44.6MCall Options Held
226KPut Options Held
909K-
Vanguard Group Inc Valley Forge, PA4.22MShares$12.4 Million0.0% of portfolio
-
Aqr Capital Management LLC Greenwich, CT3.34MShares$9.82 Million0.01% of portfolio
-
Black Rock Inc. New York, NY2.67MShares$7.85 Million0.0% of portfolio
-
Goldman Sachs Group Inc New York, NY2.61MShares$7.67 Million0.0% of portfolio
-
Almitas Capital LLC Santa Monica, CA1.9MShares$5.6 Million1.57% of portfolio
About Amylyx Pharmaceuticals, Inc.
- Ticker AMLX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 58,533,200
- Market Cap $172M
- Description
- Amylyx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing various therapeutics for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. The company's product pipeline includes AMX0035, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment...